Company Overview
Illumina, Inc. operates as a leading provider of sequencing- and array-based solutions designed for comprehensive genetic and genomic analysis across global markets including the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company's core business involves offering specialized instruments and consumables, such as reagents, flow cells, and other essential components required for high-throughput genetic testing and research applications. This entity functions within the Healthcare sector, specifically targeting the Diagnostics & Research industry, which implies a focus on technologies that support medical diagnosis, scientific research, and precision medicine initiatives. In terms of scale, Illumina holds a market capitalization of $19.36B and reported annual revenue of $4.34B, supported by an employee base of 8600 individuals. These financial dimensions indicate that the company commands a substantial position within the genomic sequencing landscape, reflecting significant market penetration and operational capacity relative to peers in the biotechnology and healthcare technology space.
Financial Health
The company reported revenue of $4.34B for the trailing twelve months, with a net income of $850.00M and an EBITDA of $1.14B. The gap between the $4.34B in revenue and the $850.00M in net income reveals a cost structure where operating expenses, including cost of goods sold and overhead, consume approximately 80.4% of total sales before reaching the bottom line. Free cash flow stands at $786.00M, which signifies that the company generates sufficient cash from operations to cover capital expenditures and still maintain a robust reserve for strategic investments or debt servicing. The company's balance sheet demonstrates strong profitability efficiency, evidenced by a gross margin of 68.2%, an operating margin of 19.7%, and a profit margin of 19.6%. These margin figures indicate that the business model enjoys high pricing power and operational leverage, allowing a significant portion of revenue to convert into profit after accounting for direct production costs and broader operational overhead. Regarding liquidity and leverage, Illumina holds $1.63B in cash against $2.55B in debt, resulting in a debt-to-equity ratio of 93.76. While the debt load is present, the current ratio of 2.08 suggests that the company possesses more than double the current assets needed to cover its short-term liabilities, indicating a conservative approach to short-term liquidity management. Furthermore, the return on equity is 33.4% and the return on assets is 8.4%, metrics that reveal management's effectiveness in generating substantial returns on shareholder capital while maintaining a moderate return relative to the total asset base utilized to generate those earnings.
Valuation Assessment
The stock carries a trailing P/E ratio of 23.18 and a forward P/E of 21.69. The difference between these two metrics, with the forward P/E being lower, implies that the market expects earnings to grow in the coming periods, thereby reducing the multiple required to value future earnings. The price-to-book ratio is 7.11, which indicates that the market values the company at a significant premium over its net asset book value, suggesting confidence in the intangible assets and future growth potential of the genomic technology. Alternative valuation metrics such as the price-to-sales ratio of 4.46 and an EV/EBITDA of 17.80 provide context on how the company is priced relative to its sales volume and earnings power before interest, taxes, depreciation, and amortization. In terms of price range, the 52-week high is $155.53 and the 52-week low is $68.70. Without a specific current share price provided in the data, the valuation context remains anchored to this established trading range which defines the historical volatility floor and ceiling for the security. The beta value is 1.50, which means the stock price is expected to be 50% more volatile than the broader market index, reflecting higher sensitivity to market movements and specific sector risks.
Growth & Income
Revenue growth for the year over year is 5.0%, while earnings growth for the same period is 86.4%. Earnings are growing at a rate significantly faster than revenue, which implies that the company is improving its cost efficiency, expanding margins, or benefiting from a one-time gain that is not yet reflected in top-line sales. Illumina does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its earnings into growth initiatives, research and development, and capital expansion rather than distributing cash to shareholders. This strategy prioritizes capital allocation for long-term technological advancement over immediate income generation for investors. The overall growth and income profile is characterized by high earnings acceleration driven by operational improvements rather than top-line expansion, combined with a zero-dividend policy that directs all capital back into the business for future scalability.